首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1635981

2025-2033 年高血磷症藥物市場報告（依產品、劑型、配銷通路及地區）

Hyperphosphatemia Drugs Market Report by Product, Dosage Form, Distribution Channel, and Region 2025-2033

出版日期: 2025年01月10日 | 出版商:

IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

2024年全球IMARC Group血磷症藥物市場規模達44億美元。末期腎病（ESKD）盛行率的上升、易患慢性疾病的老年人口的大幅增加以及健康意識的提高導致早期疾病診斷的趨勢不斷上升，這些都是推動市場發展的一些關鍵因素。

高磷酸鹽血症的特徵是由於磷酸鹽攝取增加、磷酸鹽遷移出細胞、磷酸鹽排泄減少導致血液中磷酸鹽水平升高。高磷血症常見於患有慢性腎臟疾病、糖尿病酮酸中毒、未控制的糖尿病和副甲狀腺素水平低的人。治療高血磷症的藥物往往含有磷酸鹽結合劑，有助於控制血液中磷酸鹽的高濃度。此外，高磷血症藥物可有效減少胃腸道對磷的吸收。它們將陰離子磷酸鹽與活性陽離子（例如碳酸鹽、乙酸鹽、羥基氧化物或檸檬酸鹽）交換，形成不可吸收和排泄的化合物。

高血磷症藥物市場趨勢：

全球各種慢性疾病，特別是末期腎病（ESKD）盛行率的上升是推動市場成長的重要因素。這可以歸因於易患這些疾病的老年人口數量大幅增加。與此一致的是，由於新藥批准而推出的產品數量不斷增加，對市場產生了積極影響。此外，在眾多臨床試驗中引入強大的管道藥物正在為市場創造利潤豐厚的成長機會。然而，高磷血症藥物日益嚴重的副作用、多個國家藥品管理機構監管的日益嚴格以及高昂的生產成本正在限制市場的成長。相反，藥品生產過程中廣泛的研發（R＆D）活動正在為市場創造積極的前景。除此之外，主要參與者為擴大其地理影響力而大幅增加的合作、夥伴關係和策略併購（M&A）也為市場提供了動力。人們對傳統磷酸鹽結合劑藥物的偏好轉變為採用非磷酸鹽結合劑藥物，進一步推動了市場的發展。此外，不斷增加的醫療支出以及醫療基礎設施的持續技術改進正在推動市場。推動該市場的其他一些因素包括快速城市化、產品高階化、早期疾病診斷的上升趨勢、生物技術行業的大幅成長以及可支配收入水平的提高。

本報告回答的關鍵問題：

迄今為止，全球高血磷症藥物市場表現如何，未來幾年將如何表現？
全球高磷血症藥物市場的促進因素、限制因素和機會是什麼？
主要區域市場有哪些？
哪些國家代表了最具吸引力的高血磷症藥物市場？
基於產品的市場區隔是什麼？
根據劑型，市場的詳細情形如何？
基於配銷通路的市場區隔是什麼？
全球高血磷症藥物市場競爭格局如何？
全球高血磷症藥物市場的主要參與者/公司有哪些？

The global hyperphosphatemia drugs market size reached USD 4.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2033, exhibiting a growth rate (CAGR) of 6.72% during 2025-2033. The rising prevalence of end stage kidney disease (ESKD), considerable rise in the geriatric population that is susceptible to developing chronic ailments and the increasing health consciousness resulting in the rising trend of early disease diagnosis represent some of the key factors driving the market.

Hyperphosphatemia is characterized by an elevated level of phosphate in the blood as a result of increased intake of phosphate, migration of phosphate out of the cells, and decreased excretion of phosphate. Hyperphosphatemia is frequently found in people who suffer from chronic kidney diseases, diabetic ketoacidosis, uncontrolled diabetes, and low parathyroid hormone levels. Medications for hyperphosphatemia, which tend to contain phosphate binders, help control the high levels of phosphate in the blood. Additionally, hyperphosphatemia drugs are effective at reducing phosphorus absorption through the gastrointestinal tract. They exchange an anion phosphate with an active cation, such as carbonate, acetate, oxyhydroxide, or citrate, to form a compound that is nonabsorbable and excreted.

Hyperphosphatemia Drugs Market Trends:

The rising prevalence of various chronic diseases, particularly end stage kidney disease (ESKD), across the globe is a significant factor driving the growth of the market. This can be attributed to a considerable rise in the geriatric population that is susceptible to developing these ailments. In line with this, the increasing number of product launches due to the approval of novel drugs are positively impacting the market. Also, the introduction of strong pipeline drugs in numerous clinical trials is creating lucrative growth opportunities in the market. However, the growing side effects of hyperphosphatemia drugs, the rising stringency in regulations by the drug-governing bodies in several countries, and high production costs are restraining the market growth. On the contrary, extensive research and development (R&D) activities in drug manufacturing procedures are creating a positive outlook for the market. Apart from this, a significant increase in collaborations, partnerships and strategic merger and acquisition (M&As) by the key players to extend their geographical presence is also providing an impetus to the market. The market is further fueled by the shifting preference toward the adoption of non-phosphate binder drugs from the conventional phosphate binder drugs. Moreover, the increasing medical expenditure, along with continual technological improvements in the healthcare infrastructure facilities, are propelling the market. Some of the other factors contributing to the market include rapid urbanization, product premiumization, the rising trend of early disease diagnosis, considerable growth in the biotechnology industry and inflating disposable income levels.

Key Market Segmentation:

Product Insights:

Sevelamer
Calcium Based Phosphate Binders
Iron Based Phosphate Binders
Lanthanum Carbonate
Others

Dosage Form Insights:

Tablets
Syrups
Capsules

Distribution Channel Insights:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Regional Insights:

North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for hyperphosphatemia drugs. Some of the factors driving the North America hyperphosphatemia drugs market include the increasing number of product launches due to the approval of novel drugs, extensive research and development (R&D) activities conducted by key players, and the growing medical expenditure, along with continual technological improvements in healthcare infrastructure facilities.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global hyperphosphatemia drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Ardelyx Inc., Fresenius Medical Care AG & Co. KGaA, Lupin Pharmaceuticals Inc (Lupin Limited), Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.), Vifor Pharma Management Ltd. (CSL Limited), etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report:

How has the global hyperphosphatemia drugs market performed so far and how will it perform in the coming years?
What are the drivers, restraints, and opportunities in the global hyperphosphatemia drugs market?
What are the key regional markets?
Which countries represent the most attractive hyperphosphatemia drugs markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the dosage form?
What is the breakup of the market based on the distribution channel?
What is the competitive structure of the global hyperphosphatemia drugs market?
Who are the key players/companies in the global hyperphosphatemia drugs market?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Hyperphosphatemia Drugs Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Sevelamer
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Calcium Based Phosphate Binders
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Iron Based Phosphate Binders
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Lanthanum Carbonate
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
6.5 Others
- 6.5.1 Market Trends
- 6.5.2 Market Forecast

7 Market Breakup by Dosage Form

7.1 Tablets
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Syrups
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Capsules
- 7.3.1 Market Trends
- 7.3.2 Market Forecast

8 Market Breakup by Distribution Channel

8.1 Hospital Pharmacies
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Retail Pharmacies
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Online Pharmacies
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Region

9.1 North America
- 9.1.1 United States
  - 9.1.1.1 Market Trends
  - 9.1.1.2 Market Forecast
- 9.1.2 Canada
  - 9.1.2.1 Market Trends
  - 9.1.2.2 Market Forecast
9.2 Asia-Pacific
- 9.2.1 China
  - 9.2.1.1 Market Trends
  - 9.2.1.2 Market Forecast
- 9.2.2 Japan
  - 9.2.2.1 Market Trends
  - 9.2.2.2 Market Forecast
- 9.2.3 India
  - 9.2.3.1 Market Trends
  - 9.2.3.2 Market Forecast
- 9.2.4 South Korea
  - 9.2.4.1 Market Trends
  - 9.2.4.2 Market Forecast
- 9.2.5 Australia
  - 9.2.5.1 Market Trends
  - 9.2.5.2 Market Forecast
- 9.2.6 Indonesia
  - 9.2.6.1 Market Trends
  - 9.2.6.2 Market Forecast
- 9.2.7 Others
  - 9.2.7.1 Market Trends
  - 9.2.7.2 Market Forecast
9.3 Europe
- 9.3.1 Germany
  - 9.3.1.1 Market Trends
  - 9.3.1.2 Market Forecast
- 9.3.2 France
  - 9.3.2.1 Market Trends
  - 9.3.2.2 Market Forecast
- 9.3.3 United Kingdom
  - 9.3.3.1 Market Trends
  - 9.3.3.2 Market Forecast
- 9.3.4 Italy
  - 9.3.4.1 Market Trends
  - 9.3.4.2 Market Forecast
- 9.3.5 Spain
  - 9.3.5.1 Market Trends
  - 9.3.5.2 Market Forecast
- 9.3.6 Russia
  - 9.3.6.1 Market Trends
  - 9.3.6.2 Market Forecast
- 9.3.7 Others
  - 9.3.7.1 Market Trends
  - 9.3.7.2 Market Forecast
9.4 Latin America
- 9.4.1 Brazil
  - 9.4.1.1 Market Trends
  - 9.4.1.2 Market Forecast
- 9.4.2 Mexico
  - 9.4.2.1 Market Trends
  - 9.4.2.2 Market Forecast
- 9.4.3 Others
  - 9.4.3.1 Market Trends
  - 9.4.3.2 Market Forecast
9.5 Middle East and Africa
- 9.5.1 Market Trends
- 9.5.2 Market Breakup by Country
- 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

10.1 Overview
10.2 Drivers
10.3 Restraints
10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
- 14.3.1 Ardelyx Inc.
  - 14.3.1.1 Company Overview
  - 14.3.1.2 Product Portfolio
  - 14.3.1.3 Financials
- 14.3.2 Fresenius Medical Care AG & Co. KGaA
  - 14.3.2.1 Company Overview
  - 14.3.2.2 Product Portfolio
  - 14.3.2.3 Financials
  - 14.3.2.4 SWOT Analysis
- 14.3.3 Lupin Pharmaceuticals Inc (Lupin Limited)
  - 14.3.3.1 Company Overview
  - 14.3.3.2 Product Portfolio
- 14.3.4 Torii Pharmaceutical Co. Ltd. (Japan Tobacco Inc.)
  - 14.3.4.1 Company Overview
  - 14.3.4.2 Product Portfolio
  - 14.3.4.3 Financials
- 14.3.5 Vifor Pharma Management Ltd. (CSL Limited)
  - 14.3.5.1 Company Overview
  - 14.3.5.2 Product Portfolio

Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

簡介目錄圖表

List of Figures

Figure 1: Global: Hyperphosphatemia Drugs Market: Major Drivers and Challenges
Figure 2: Global: Hyperphosphatemia Drugs Market: Sales Value (in Billion USD), 2019-2024
Figure 3: Global: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
Figure 4: Global: Hyperphosphatemia Drugs Market: Breakup by Product (in %), 2024
Figure 5: Global: Hyperphosphatemia Drugs Market: Breakup by Dosage Form (in %), 2024
Figure 6: Global: Hyperphosphatemia Drugs Market: Breakup by Distribution Channel (in %), 2024
Figure 7: Global: Hyperphosphatemia Drugs Market: Breakup by Region (in %), 2024
Figure 8: Global: Hyperphosphatemia Drugs (Sevelamer) Market: Sales Value (in Million USD), 2019 & 2024
Figure 9: Global: Hyperphosphatemia Drugs (Sevelamer) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 10: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market: Sales Value (in Million USD), 2019 & 2024
Figure 11: Global: Hyperphosphatemia Drugs (Calcium Based Phosphate Binders) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 12: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market: Sales Value (in Million USD), 2019 & 2024
Figure 13: Global: Hyperphosphatemia Drugs (Iron Based Phosphate Binders) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 14: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market: Sales Value (in Million USD), 2019 & 2024
Figure 15: Global: Hyperphosphatemia Drugs (Lanthanum Carbonate) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 16: Global: Hyperphosphatemia Drugs (Other Products) Market: Sales Value (in Million USD), 2019 & 2024
Figure 17: Global: Hyperphosphatemia Drugs (Other Products) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 18: Global: Hyperphosphatemia Drugs (Tablets) Market: Sales Value (in Million USD), 2019 & 2024
Figure 19: Global: Hyperphosphatemia Drugs (Tablets) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 20: Global: Hyperphosphatemia Drugs (Syrups) Market: Sales Value (in Million USD), 2019 & 2024
Figure 21: Global: Hyperphosphatemia Drugs (Syrups) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 22: Global: Hyperphosphatemia Drugs (Capsules) Market: Sales Value (in Million USD), 2019 & 2024
Figure 23: Global: Hyperphosphatemia Drugs (Capsules) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 24: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 25: Global: Hyperphosphatemia Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 26: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 27: Global: Hyperphosphatemia Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 28: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
Figure 29: Global: Hyperphosphatemia Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 30: North America: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 31: North America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 32: United States: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 33: United States: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 34: Canada: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 35: Canada: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 36: Asia-Pacific: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 37: Asia-Pacific: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 38: China: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 39: China: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 40: Japan: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 41: Japan: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 42: India: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 43: India: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 44: South Korea: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 45: South Korea: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 46: Australia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 47: Australia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 48: Indonesia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 49: Indonesia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 50: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 51: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 52: Europe: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 53: Europe: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 54: Germany: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 55: Germany: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 56: France: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 57: France: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 58: United Kingdom: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 59: United Kingdom: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 60: Italy: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 61: Italy: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 62: Spain: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 63: Spain: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 64: Russia: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 65: Russia: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 66: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 67: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 68: Latin America: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 69: Latin America: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 70: Brazil: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 71: Brazil: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 72: Mexico: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 73: Mexico: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 74: Others: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 75: Others: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 76: Middle East and Africa: Hyperphosphatemia Drugs Market: Sales Value (in Million USD), 2019 & 2024
Figure 77: Middle East and Africa: Hyperphosphatemia Drugs Market: Breakup by Country (in %), 2024
Figure 78: Middle East and Africa: Hyperphosphatemia Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
Figure 79: Global: Hyperphosphatemia Drugs Industry: Drivers, Restraints, and Opportunities
Figure 80: Global: Hyperphosphatemia Drugs Industry: Value Chain Analysis
Figure 81: Global: Hyperphosphatemia Drugs Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Hyperphosphatemia Drugs Market: Key Industry Highlights, 2024 & 2033
Table 2: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Product (in Million USD), 2025-2033
Table 3: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Dosage Form (in Million USD), 2025-2033
Table 4: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
Table 5: Global: Hyperphosphatemia Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
Table 6: Global: Hyperphosphatemia Drugs Market: Competitive Structure
Table 7: Global: Hyperphosphatemia Drugs Market: Key Players

02-2729-4219

+886-2-2729-4219

License/價格

FAQ

2025-2033 年高血磷症藥物市場報告（依產品、劑型、配銷通路及地區）

Hyperphosphatemia Drugs Market Report by Product, Dosage Form, Distribution Channel, and Region 2025-2033

高血磷症藥物市場趨勢：

本報告回答的關鍵問題：

目錄

第1章：前言

第 2 章：範圍與方法

第 3 章：執行摘要

第 4 章：簡介

第 5 章：全球高血磷症藥物市場

第 6 章：市場區隔：依產品

第 7 章：市場區隔：按劑型

第 8 章：市場區隔：按配銷通路

第 9 章：市場區隔：按地區

第 10 章：促進因素、限制與機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

第 13 章：價格分析

第14章：競爭格局